Atsuko Kawasaki
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Phase I study of glofitamab in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Journal: International journal of clinical oncology
Published: January 15, 2026
Efficacy and safety of subcutaneous mosunetuzumab in combination with lenalidomide and as a monotherapy in Japanese patients with relapsed/refractory follicular lymphoma.
Journal: International journal of clinical oncology
Published: October 29, 2025
Patient Preference on Age-Related Macular Degeneration Treatment: A Systematic Review.
Journal: Patient preference and adherence
Published: January 16, 2025
Efficacy and safety of mosunetuzumab monotherapy for Japanese patients with relapsed/refractory follicular lymphoma: FLMOON-1.
Journal: International journal of clinical oncology
Published: September 06, 2024
Correction to: Phase I study of the anti‑TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: March 31, 2024
Phase I study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in Japanese patients with advanced or metastatic solid tumors.
Journal: Cancer chemotherapy and pharmacology
Published: August 24, 2023
Dose-escalation part of Phase I study of single-agent mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
Journal: Japanese journal of clinical oncology
Published: March 23, 2023
Showing 1-8 of 8
Last Updated: 09/26/2026